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Lesch–Nyhan disease is a neurogenetic disorder caused by deﬁciency of the enzyme hypoxanthine–guanine phosphoribosyl-
transferase. The classic form of the disease is described by a characteristic syndrome that includes overproduction of uric acid,
severe generalized dystonia, cognitive disability and self-injurious behaviour. In addition to the classic disease, variant forms of
the disease occur wherein some clinical features are absent or unusually mild. The current studies provide the results of a
prospective and multi-centre international study focusing on neurological manifestations of the largest cohort of Lesch–Nyhan
disease variants evaluated to date, with 46 patients from 3 to 65 years of age coming from 34 families. All had evidence for
overproduction of uric acid. Motor abnormalities were evident in 42 (91%), ranging from subtle clumsiness to severely disabling
generalized dystonia. Cognitive function was affected in 31 (67%) but it was never severe. Though none exhibited self-injurious
behaviours, many exhibited behaviours that were maladaptive. Only three patients had no evidence of neurological dysfunction.
Our results were compared with a comprehensive review of 78 prior reports describing a total of 127 Lesch–Nyhan disease
variants. Together these results deﬁne the spectrum of clinical features associated with hypoxanthine–guanine phosphoribosyl-
transferase deﬁciency. At one end of the spectrum are patients with classic Lesch–Nyhan disease and the full clinical phenotype.
At the other end of the spectrum are patients with overproduction of uric acid but no apparent neurological or behavioural
deﬁcits. Inbetween are patients with varying degrees of motor, cognitive, or behavioural abnormalities. Recognition of this
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Introduction
Complete deﬁciency of the purine recycling enzyme, hypox-
anthine–guanine phosphoribosyltransferase (HPRT), causes Lesch-
Nyhan disease (LND). Affected individuals typically suffer from
overproduction of uric acid that may lead to hyperuricaemia,
nephrolithiasis, gout or subcutaneous deposits of tophi (Lesch
and Nyhan, 1964; Jinnah and Friedmann, 2001). Neurologically,
all patients have severe motor disability that is dominated by dys-
tonia, with occasional choreoathetosis or spasticity (Jinnah et al.,
2006). Most also exhibit recurrent self-injurious behaviour, often
with other difﬁcult behaviours such as impulsivity, striking or
spitting at others, or use of socially unacceptable language
(Nyhan, 1976; Anderson and Ernst, 1994; Schretlen et al.,
2005). Finally, most have intellectual disability (Anderson et al.,
1992; Matthews et al., 1995; Schretlen et al., 2001).
Although complete HPRT deﬁciency typically results in the
stereotypical LND syndrome, partial deﬁciency more often causes
a phenotype in which some features are attenuated or absent
(Kelley et al., 1969; Emmerson and Thompson, 1973; Jinnah
and Friedmann, 2001; Puig et al., 2001). Collectively, these
patients are labelled LND variants. All of these patients produce
excess uric acid, but broad variations in the neurological and
behavioural features have been described. Because all patients
overproduce uric acid, efforts to classify the spectrum of disease
have focussed on differences in neurological and behavioural
manifestations. Initial attempts classiﬁed patients in two groups,
including those with the complete phenotype, and those with only
minor neurobehavioural manifestations (Kelley et al., 1969).
However, increasing recognition of cases with intermediate sever-
ity led to later classiﬁcation systems that involved three or four
groups, based on speciﬁc neurobehavioural features. The earliest
of these focussed on differences in intellectual function (Page
et al., 1981; Hersh et al., 1986; Page and Nyhan, 1989). This
focus proved difﬁcult because of challenges inherent in compre-
hensive cognitive assessments, together with wide variations in
normal individuals. More recent proposals have focussed on vari-
ations in the motor disorder (Sege-Peterson et al., 1992; Jinnah
et al., 2000; Puig et al., 2001).
Most proposed nosological classiﬁcation systems were derived
from relatively small numbers of patients evaluated at individual
centres, each with different assessment protocols and varying
expertise with the many manifestations. These studies have led
to different opinions on the relative importance of individual clin-
ical features for classiﬁcation. The goal of the current studies was
to delineate more comprehensively the spectrum of neurological
abnormalities in an international multi-centre study of a large
group of LND variants.
Materials and methods
Patients
All 46 LND variants were recruited after referral to centres with exper-
tise in the evaluation and management of LND and related conditions.
The diagnosis of a variant form of LND required evidence for an HPRT
gene mutation or reduced HPRT enzyme activity in a male patient
without the self-injurious behaviour typical of classic cases. Self-injur-
ious behaviour was deﬁned as any self-directed behaviour leading to
tissue injury. Neurological and/or behavioural difﬁculties were not
required in the LND variants.
Since the main focus was the LND variants, classic cases of LND
were excluded. The diagnosis of classic LND was made in accordance
with prior studies (Jinnah et al., 2006) and included expression of the
full phenotype with evidence for overproduction of uric acid, severe
motor disability, cognitive dysfunction and self-injurious behaviour.
The diagnosis of classic LND was supported by documentation of an
HPRT gene mutation predicting null activity or reduced HPRT enzyme
activity in ﬁbroblasts or blood cells. Although classic LND cases were
not evaluated for this study, data from our previously published cases
are presented for comparisons (Jinnah et al., 2006).
Evaluation
The ﬁrst author directly evaluated 37 patients. Nine others were eval-
uated by clinicians who worked with the ﬁrst author on other cases,
and videotapes were prepared for review. The evaluation included a
detailed history with attention to early development and behaviour. It
also included a complete neurological examination with speciﬁc atten-
tion to the motor features as previously described (Jinnah et al., 2006).
Because dystonia was the most common and severe problem, the
Burke–Fahn–Marsden (BFM) rating scale was used to estimate overall
severity of motor dysfunction (Burke et al., 1985). Results from neu-
ropsychological or diagnostic testing were summarized when available
from the clinical records or prior studies (Schretlen et al., 2001).
Literature review
The Medline database through July 2009 was searched for reports
with the keywords ‘Lesch–Nyhan’, ‘hypoxanthine–guanine phosphor-
ibosyltransferase’, or ‘Kelley–Seegmiller’. Other reports were found
through the bibliographies of these articles.
Among 78 articles describing 127 LND variants retrieved, four were
from the French literature, two were from the German literature, one
was from the Spanish literature and the rest were in English. To avoid
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any cases that were re-evaluated and presented as part of the pro-
spective evaluation were excluded from the summary of prior reports,
leaving 109 unique cases in 60 reports.
Prospective evaluation
Demographics
All 46 LND variants were male, ranging from 3 to 65 years of age
(Table 1). Most were taking allopurinol to reduce uric acid, and three
were taking antihypertensives. Other medications occasionally used to
reduce excess muscle tone included baclofen, benzodiazepines and
trihexyphenidyl.
Presentation
Information concerning presenting signs was available for 44 cases
(96%). The most frequent presenting problems were neurological, in
26 cases (Table 1). Delayed acquisition of motor or speech skills in
early childhood was common. Another 18 patients came to medical
attention as a result of overproduction of uric acid. Among these were
eight with gout, six with problems involving the kidneys or urogenital
tract, four with asymptomatic hyperuricaemia and one with a tophus.
Motor function
Motor abnormalities occurred in 42 patients (91%). Functional severity
varied from incapacitating to barely detectable with speciﬁc tasks. The
most seriously affected cases exhibited a motor syndrome indistin-
guishable from classic LND, with profoundly disabling and generalized
dystonia. Among the LND variants with prominent dystonia, two had
chorea and ballism and two had dystonic myoclonus. Moderately
affected patients were less disabled but exhibited dystonia with repet-
itive abnormal posturing of the limbs and overﬂow posturing. Mildly
affected cases had dystonic overﬂow only when performing speciﬁc
tasks, or exercise-induced dystonia. The least severely affected cases
had subtle motor signs that were clearly abnormal but not readily
classiﬁed as dystonic. Examples included slight slowing or clumsiness
of ﬁne dexterous movements of the ﬁngers and hands, or an awkward
or stiff-appearing gait. Overall, obvious dystonic movements were evi-
dent in 27 (58.7%), probable dystonia limited to overﬂow posturing
was seen in ﬁve (10.9%), and possible dystonia deﬁned only by slow
or awkward movements without overt twisting or posturing occurred
in seven (15.2%).
Although slight slowing of movements was common, signiﬁcant
bradykinesia was evident only for four. Other parkinsonian features
included resting tremor in two, rigidity without cogwheeling in two,
rigidity with cogwheeling in one, hypomimia in two, and hypophonia
in one. Mild postural or kinetic tremors occurred in two. Three had
tic-like movements.
Pyramidal signs also were common. Hyperreﬂexia occurred in 23
(50%), being limited to the legs in 12 and the arms in one. Clonus
occurred in 14, limited to the ankles. Only three had a rate-dependent
increase in limb tone with a catch indicative of spasticity. The fre-
quency of the extensor plantar reﬂex was not summarized because
it could not be discriminated reliably from the dystonic toe response
(Nausieda et al., 1980; Ashour et al., 2005).
Some patients also exhibited irregular timing and coordination of
movements suggestive of cerebellar ataxia, for example overshooting
a target on ﬁnger-to-nose pointing or irregular hand tapping.
However, all of these patients also had severe generalized dystonia,
and their irregular movements seemed more related to dystonic dys-
function than true cerebellar ataxia. More deﬁnitive features indicative
of cerebellar involvement were absent, including isolated ataxia, ocular
hypermetria or nystagmus, or scanning speech.
Speech
Dysarthria occurred in 35 cases (76%), developing in all during early
childhood. The most severely affected had obvious dystonic dysarthria
with slow and laboured articulation accompanied by overactivity of
orolingual and jaw muscles, with overﬂow to other craniofacial mus-
cles. In these patients, speech often was limited to single words or
short phrases, and was difﬁcult to follow. Moderately affected patients
exhibited speech that was slow and laboured, often with overﬂow
muscle activation typical of dystonia. A task-speciﬁc jaw dystonia
occurred with speaking in three, and six had stuttering or hesitant
speech. Less severely affected patients had speech that was difﬁcult
to characterize, being only slightly indistinct or slow. The least severely
affected patients had histories of transient speech impediment during
childhood or transient decompensation as adults during periods of
stress or fatigue.
One patient had a high-pitched nasal voice suggestive of spastic
dysarthria. Eleven had normal speech. Vocal cord involvement sugges-
tive of spasmodic dysphonia was absent.
Gait
A gait disorder occurred in 33 cases (72%), emerging typically during
childhood. Those most severely affected could not stand or walk, with
the dominating problem being hypotonia with superimposed dystonic
posturing of the legs and trunk with attempts to stand or walk. In
these cases, muscle bulk was signiﬁcantly reduced distally in the legs
due to disuse. Moderately affected patients could stand with support,
but independent ambulation was difﬁcult due to leg or trunk postur-
ing. Less severely affected cases exhibited a very laboured and
stiff-appearing gait, with overﬂow activation of truncal or limb mus-
cles. In the least severely affected cases, the gait had a stiff or heavy
appearance without other obvious signs of dystonia. Thirteen had
normal gaits.
Cognition
Cognitive skills varied from moderately impaired to above normal.
Some type of learning impediment was evident in 31 cases (67%).
This impediment was expressed as a need for special education, or
being recognized as a slow learner in school. Attention-deﬁcit hyper-
activity disorder (ADHD) was diagnosed in seven. Several others were
described by parents as having problems with attention but were not
formally diagnosed.
Formal neuropsychological testing was available for 21 patients
(Table 2). Most fell in the mildly impaired to low-average range.
Only seven had IQ scores of 90 or above, and two of these were
diagnosed with ADHD. No case had severe cognitive disability. The
most seriously affected case was also unusual with dysmorphic fea-
tures suggestive of a superimposed congenital defect (Table 1).
Behaviour
Overt self-injurious behaviour was absent because it was an exclusion
criterion. However, some LND variants exhibited potentially related
behaviours. For example, severe onychophagia was evident in six
cases. Obsessive-compulsive disorder and an anxiety disorder were
diagnosed in one patient each. Other psychosocial problems included
ﬁve with impulsivity (including two severe enough to quality for
impulse control disorder), four with clinically apparent problems with
Lesch–Nyhan variants Brain 2010: 133; 671–689 | 673T
a
b
l
e
1
C
a
s
e
d
e
m
o
g
r
a
p
h
i
c
s
C
a
s
e
-
f
a
m
i
l
y
O
t
h
e
r
i
d
e
n
t
i
ﬁ
e
r
s
H P R T
m
u
t
a
t
i
o
n
C
o
n
s
e
-
q
u
e
n
c
e
R
e
s
i
d
u
a
l
f
u
n
c
t
i
o
n
a
P
r
e
s
e
n
t
i
n
g
p
r
o
b
l
e
m
P
r
e
s
e
n
t
i
n
g
a
g
e
(
y
e
a
r
s
)
A
g
e
l
a
s
t
s
e
e
n
(
y
e
a
r
s
)
N
o
n
-
n
e
u
r
o
l
o
g
i
c
p
r
o
b
l
e
m
s
M
e
d
i
c
a
t
i
o
n
s
P
r
i
o
r
r
e
p
o
r
t
s
1
–
1
N
o
n
e
2
3
9
-
2
4
0
d
e
l
G
A
i
n
s
T
T
D
8
0
F
N
D
(
E
L
)
M
o
t
o
r
d
e
l
a
y
a
n
d
p
o
s
t
u
r
i
n
g
0
.
5
3
.
4
M
u
l
t
i
p
l
e
s
c
a
r
s
o
n
h
a
n
d
s
A
l
l
o
p
u
r
i
n
o
l
,
d
i
a
z
e
p
a
m
N
o
n
e
2
–
2
P
B
I
V
S
4
-
1
G
4
A
S
p
l
i
c
e
e
r
r
o
r
N
D
(
E
L
)
N
e
p
h
r
o
l
i
t
h
i
a
s
i
s
0
.
2
5
7
A
l
l
o
p
u
r
i
n
o
l
N
o
n
e
3
–
3
J
L
Y
I
V
S
1
+
1
G
4
A
S
p
l
i
c
e
e
r
r
o
r
0
.
1
%
(
E
L
)
H
y
p
o
t
o
n
i
a
0
.
5
7
N
e
p
h
r
o
l
i
t
h
i
a
s
i
s
,
h
y
d
r
o
n
e
p
h
r
o
s
i
s
A
l
l
o
p
u
r
i
n
o
l
,
b
a
c
l
o
f
e
n
(
M
a
r
c
u
s
e
t
a
l
.
,
1
9
9
3
)
4
–
4
Z
a
r
a
z
o
g
a
I
G
3
9
7
A
V
1
3
3
M
9
.
4
%
(
E
L
)
,
5
4
%
(
L
E
)
R
e
n
a
l
f
a
i
l
u
r
e
I
n
f
a
n
c
y
8
R
e
n
a
l
i
n
s
u
f
ﬁ
c
i
e
n
c
y
A
l
l
o
p
u
r
i
n
o
l
(
J
i
n
n
a
h
e
t
a
l
.
,
2
0
0
0
T
o
r
r
e
s
e
t
a
l
.
,
2
0
0
0
;
P
u
i
g
e
t
a
l
.
,
2
0
0
1
)
5
–
5
N
F
T
2
0
3
C
L
6
8
P
N
D
(
E
L
)
M
o
t
o
r
d
e
l
a
y
0
.
5
9
N
e
p
h
r
o
c
a
l
c
i
n
o
s
i
s
A
l
l
o
p
u
r
i
n
o
l
N
o
n
e
6
–
6
D
o
A
G
1
4
3
A
R
4
8
H
N
D
(
E
L
)
M
o
t
o
r
d
e
l
a
y
2
9
N
e
p
h
r
o
l
i
t
h
i
a
s
i
s
A
l
l
o
p
u
r
i
n
o
l
N
o
n
e
7
–
7
J
W
C
1
9
3
T
L
6
5
P
1
0
%
(
E
L
)
M
o
t
o
r
d
e
l
a
y
6
1
0
H
y
p
e
r
t
e
n
s
i
o
n
A
l
l
o
p
u
r
i
n
o
l
,
c
e
t
i
r
i
z
i
n
e
(
S
r
i
v
a
s
t
a
v
a
e
t
a
l
.
,
2
0
0
2
)
8
–
8
P
4
N
o
n
e
m
R
N
A
d
e
c
r
e
a
s
e
6
%
(
E
L
)
,
9
8
%
(
L
E
)
H
y
p
e
r
u
r
i
c
a
e
m
i
a
1
0
1
0
N
A
(
G
a
r
c
i
a
e
t
a
l
.
,
2
0
0
8
)
9
–
5
D
i
A
T
2
0
3
C
p
r
e
s
u
m
e
d
L
6
8
P
7
%
(
E
L
)
M
o
t
o
r
d
e
l
a
y
2
1
1
N
A
A
l
l
o
p
u
r
i
n
o
l
N
o
n
e
1
0
–
8
P
3
N
o
n
e
m
R
N
A
d
e
c
r
e
a
s
e
6
%
(
E
L
)
,
9
8
%
(
L
E
)
H
y
p
e
r
u
r
i
c
a
e
m
i
a
1
2
1
2
N
A
(
G
a
r
c
i
a
e
t
a
l
.
,
2
0
0
8
)
1
1
–
9
J
F
T
5
4
8
C
I
1
8
3
T
5
1
%
(
E
L
)
8
%
(
L
F
)
M
o
t
o
r
d
e
l
a
y
I
n
f
a
n
c
y
1
4
N
A
A
l
l
o
p
u
r
i
n
o
l
(
H
e
r
s
h
e
t
a
l
.
,
1
9
8
6
;
S
e
g
e
-
P
e
t
e
r
s
o
n
e
t
a
l
.
,
1
9
9
2
;
J
i
n
n
a
h
e
t
a
l
.
,
2
0
0
0
;
)
1
2
–
8
P
2
N
o
n
e
m
R
N
A
d
e
c
r
e
a
s
e
6
%
(
E
L
)
,
9
8
%
(
L
E
)
H
y
p
e
r
u
r
i
c
a
e
m
i
a
1
5
1
6
N
A
N
A
(
G
a
r
c
i
a
e
t
a
l
.
,
2
0
0
8
)
1
3
–
1
0
I
R
d
L
I
V
S
4
-
2
A
4
G
S
p
l
i
c
e
e
r
r
o
r
N
D
(
E
L
)
,
0
.
1
%
(
L
E
)
M
o
t
o
r
d
e
l
a
y
1
6
1
6
N
A
A
l
l
o
p
u
r
i
n
o
l
(
T
o
r
r
e
s
e
t
a
l
.
,
2
0
1
0
)
1
4
–
1
1
R
B
G
6
0
1
A
D
2
0
1
N
6
0
%
(
L
F
)
C
r
y
s
t
a
l
l
u
r
i
a
0
.
5
1
7
N
e
p
h
r
o
l
i
t
h
i
a
s
i
s
A
l
l
o
p
u
r
i
n
o
l
,
m
e
t
o
p
r
o
l
o
l
,
a
m
l
o
d
i
p
i
n
e
(
S
e
g
e
-
P
e
t
e
r
s
o
n
e
t
a
l
.
,
1
9
9
2
;
J
i
n
n
a
h
e
t
a
l
.
,
2
0
0
0
;
)
1
5
–
9
B
F
T
5
4
8
C
I
1
8
3
T
5
1
%
(
E
L
)
8
%
(
L
F
)
C
r
y
s
t
a
l
l
u
r
i
a
1
1
7
N
A
A
l
l
o
p
u
r
i
n
o
l
(
H
e
r
s
h
e
t
a
l
.
,
1
9
8
6
;
S
e
g
e
-
P
e
t
e
r
s
o
n
e
t
a
l
.
,
1
9
9
2
;
J
i
n
n
a
h
e
t
a
l
.
,
2
0
0
0
)
1
6
–
1
2
M
a
d
r
i
d
I
G
2
1
2
T
G
7
1
V
N
D
(
E
L
)
,
0
.
2
%
(
L
E
)
M
o
t
o
r
d
e
l
a
y
1
1
7
N
e
p
h
r
o
l
i
t
h
i
a
s
i
s
,
h
y
p
e
r
t
e
n
s
i
o
n
,
m
a
c
r
o
c
y
t
i
c
a
n
a
e
m
i
a
A
l
l
o
p
u
r
i
n
o
l
,
b
a
c
l
o
f
e
n
,
n
i
f
e
d
i
p
i
n
e
(
B
o
u
w
e
n
s
-
R
o
m
b
o
u
t
s
e
t
a
l
.
,
1
9
9
3
;
T
o
r
r
e
s
e
t
a
l
.
,
2
0
0
0
)
1
7
–
1
3
B
T
G
5
9
9
C
R
2
0
0
T
0
-
2
6
%
(
E
L
)
b
H
y
p
o
t
o
n
i
a
2
1
7
N
e
p
h
r
o
l
i
t
h
i
a
s
i
s
,
m
a
c
r
o
c
y
t
i
c
a
n
a
e
m
i
a
A
l
l
o
p
u
r
i
n
o
l
(
H
i
d
a
l
g
o
-
L
a
o
s
e
t
a
l
.
,
1
9
9
7
;
J
i
n
n
a
h
e
t
a
l
.
,
2
0
0
0
)
1
8
–
1
4
T
H
G
1
4
3
A
R
4
8
H
N
D
(
E
L
)
,
3
9
%
(
L
F
)
A
D
H
D
6
1
7
M
a
c
r
o
c
y
t
o
s
i
s
A
l
l
o
p
u
r
i
n
o
l
N
o
n
e
1
9
–
1
5
N
o
n
e
G
5
0
0
C
R
1
6
7
T
8
.
7
%
(
L
L
)
N
e
p
h
r
o
l
i
t
h
i
a
s
i
s
,
g
o
u
t
1
0
1
7
N
e
p
h
r
o
l
i
t
h
i
a
s
i
s
,
c
y
s
t
i
t
i
s
,
g
o
u
t
A
l
l
o
p
u
r
i
n
o
l
N
o
n
e
2
0
–
1
6
V
C
G
1
4
3
A
R
4
8
H
N
D
(
E
L
)
M
o
t
o
r
d
e
l
a
y
5
1
1
8
N
A
A
l
l
o
p
u
r
i
n
o
l
(
L
a
r
o
v
e
r
e
e
t
a
l
.
,
2
0
0
7
)
2
1
–
1
7
N
o
n
e
A
5
8
4
C
Y
1
9
5
S
N
D
(
E
L
)
U
r
i
c
a
c
i
d
c
r
y
s
t
a
l
i
n
ﬁ
n
g
e
r
1
4
1
8
N
A
N
A
(
L
a
r
o
v
e
r
e
e
t
a
l
.
,
2
0
0
4
,
2
0
0
7
)
2
2
–
1
8
M
M
I
V
S
1
+
1
G
4
T
S
p
l
i
c
e
e
r
r
o
r
5
%
(
E
L
)
,
1
%
(
L
F
)
M
o
t
o
r
d
e
l
a
y
1
2
0
M
u
l
t
i
p
l
e
s
c
a
r
s
o
n
c
h
i
n
A
l
l
o
p
u
r
i
n
o
l
,
t
r
i
h
e
x
y
p
h
e
n
i
d
y
l
,
b
a
l
c
o
f
e
n
,
d
i
a
z
e
p
a
m
(
J
i
n
n
a
h
e
t
a
l
.
,
2
0
0
0
)
2
3
–
1
4
G
H
G
1
4
3
A
R
4
8
H
1
5
%
(
L
F
)
C
l
u
m
s
i
n
e
s
s
2
.
5
2
0
M
a
c
r
o
c
y
t
o
s
i
s
A
l
l
o
p
u
r
i
n
o
l
N
o
n
e
2
4
–
1
9
P
1
N
o
n
e
D
e
c
r
e
a
s
e
d
m
R
N
A
5
%
(
E
L
)
,
6
4
%
(
L
E
)
H
y
p
e
r
u
r
i
c
a
e
m
i
a
1
4
2
0
H
y
p
o
t
h
y
r
o
i
d
i
s
m
A
l
l
o
p
u
r
i
n
o
l
(
G
a
r
c
i
a
e
t
a
l
.
,
2
0
0
8
)
2
5
–
2
0
S
a
n
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i
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r
d
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r
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p
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c
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c
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c
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c
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n
e
A
5
8
4
C
Y
1
9
5
S
N
D
(
E
L
)
M
o
t
o
r
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ﬁ
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p
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p
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u
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ﬁ
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c
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p
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b
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c
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c
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d
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i
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.
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c
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p
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P
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P
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r
d
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p
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n
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p
u
r
i
n
o
l
(
S
e
g
e
-
P
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e
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0
0
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p
u
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p
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c
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d
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p
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b
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P
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b
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e
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d
i
n
i
a
C
4
6
3
T
P
1
5
5
S
N
D
(
E
L
o
r
L
E
)
,
2
-
4
%
(
L
F
)
M
o
t
o
r
d
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u
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0
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e
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c
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l
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b
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ﬁ
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ﬁ
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c
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b
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p
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c
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c
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e
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e
r
e
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c
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i
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c
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b
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ﬁ
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ﬁ
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c
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c
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p
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c
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i
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i
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p
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p
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i
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f
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Lesch–Nyhan variants Brain 2010: 133; 671–689 | 679aggression, three others considered oppositional by parents, one who
was incarcerated for inappropriate social behaviour, and one with
Asperger syndrome.
Multiple scars under the chin from ‘repeated falls’ were seen in one
case, and two others had multiple scars on their limbs from ‘accidents’
due to ‘bad wheelchair driving’. These patients and their caregivers
did not view the scars as evidence of unwanted self-injurious beha-
viour. However, the stereotypical location in the case with chin scars
and the unusually large numbers of limb scars in the other two are
not typical of patients with other similar motor handicaps, leading the
examiners to question whether they qualiﬁed as self-injurious
behaviour.
Development and progression
Among the cases where sufﬁcient information regarding early devel-
opment could be obtained, the most common pattern involved a delay
in motor or speech development in early childhood. The most severely
affected cases were identiﬁed during their ﬁrst year of life with
hypotonia or delayed acquisition of motor milestones. Involuntary
movements evolved between 6months and 4years. Less severely
affected cases were not identiﬁed until 2–6 years of age when persis-
tent clumsiness or overﬂow posturing became increasingly apparent
with the increasingly complex motor skills expected during develop-
ment. The least severely affected cases had transient motor or speech
impediments during early childhood.
In most cases, motor disability worsened only during early childhood
and remained static thereafter. Adult-onset disability did not occur,
and there was no evidence of dementia with ageing. The lack of
progression was supported by the lack of any signiﬁcant correlation
of either BFM dystonia score or IQ with age. However, worsening
motor function with advancing age was evident for 10 cases. In
three of these, progressive gait or hand disability was attributable to
obvious joint destruction from tophaceous gout. In two others a psy-
chogenic process was suspected due to sudden onset after a traumatic
event (Table 2). The remaining ﬁve had worsening motor disability
suggestive of evolution of their neurological disorder. For example,
four with signs of mild motor delay during the ﬁrst year of life even-
tually became ambulatory, albeit with slightly clumsy gaits. Walking
became progressively awkward later in childhood or adolescence, with
development of falls severe enough to require wheelchairs by early
adulthood.
Previously reported cases
Presentation
Among 109 LND variants published, the age at presentation was
noted for 78. The average age was 12.4 years, with a range of
51month to 55 years. Initial presenting problems were reported for
97 patients (Table 3). Among these, 67 (69%) presented with issues
related to the overproduction of uric acid. There were 38 cases with
urological presentations including renal colic, renal failure, nephrolithia-
sis, haematuria, or crystalluria. Gout was the presenting problem for
26, and asymptomatic hyperuricaemia was the initial clue for three.
Only 19 (20%) presented with neurological abnormalities. Most
common were signs of delayed motor development during early
childhood.
Motor abnormalities
At any time during the illness, the most commonly reported motor
problem was dysarthria, in 19 cases (Table 4). Extrapyramidal signs
included dystonia or choreoathetosis in nine each, and athetosis in
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680 | Brain 2010: 133; 671–689 H. A. Jinnah et al.four. Pyramidal signs included hyperreﬂexia in 14, spasticity in 11 and
clonus in two.
Less frequent problems included seizures in seven, and postural or
kinetic tremors in two. One case was reported as having ataxia,
and two others were reported as suffering from a spinocerebellar syn-
drome. Another 11 were described as being clumsy or poorly coordi-
nated, or as having ‘minor’ neurological problems. Notably absent
were bradykinesia, resting tremor or cogwheel rigidity, tics or
myoclonus.
Cognitive abnormalities
Among 44 cases where cognition was addressed, formal neuropsycho-
logical testing yielded IQ scores below 90 for eight. In 16 others,
cognitive impairments were suspected on the basis of poor school
performance or other clinical benchmarks. IQ scores of 90 or greater
were documented for only four cases. Another 15 cases were consid-
ered to be cognitively normal on the basis of clinical impressions.
Behavioural abnormalities
Overt self-injurious behaviour was absent among the cases reviewed
because it was an exclusion criterion for deﬁning a variant form of
LND. However, several potentially related problems were reported.
Habitual ﬁngernail biting was noted for ﬁve cases. Impulsivity was a
problem for ﬁve cases, including one in whom the impulses were
destructive. One patient was diagnosed with hyperactivity, one with
obsessive-compulsive disorder, and another was institutionalized in a
psychiatric ward for unspeciﬁed reasons.
Discussion
The LND variants are deﬁned by HPRT deﬁciency without
self-injurious behaviour, a hallmark feature of classic LND. The
current study provides the largest and most comprehensive sum-
mary of the neurological features of these variants to date. The
relatively large number of patients permits the delineation of a
characteristic phenotype with a graded spectrum of severity,
rather than a variable assortment of unrelated abnormalities
(Fig. 1). The spectrum of variation is evident for each of the
major clinical features. Below we summarize this phenotypic spec-
trum, its relevance for nosological classiﬁcation of HPRT
deﬁciency, and its biological basis. Finally, we review the implica-
tions of phenotypic variation for diagnostic assessment and
treatment.
The spectrum of motor abnormalities
The results of our evaluations are compatible with the literature,
with small differences attributable to methodology. A shared con-
clusion is that motor abnormalities are common in the LND
variants, with a spectrum that ranges from subtle clumsiness to
severe disability. While prior reports suggest the majority of LND
variants present with problems related to uric acid, our results
suggest the majority present with neurological problems. Our stu-
dies also suggest a higher frequency of motor abnormalities in
comparison to prior reports, with a high proportion of patients
having some form of dystonia. The most likely explanation for
these differences is that the current study involved a more
methodical evaluation, which had higher sensitivity for revealing
neurobehavioural problems in comparison with the majority of
prior studies conducted by investigators specializing in genetics
or metabolic disease.
The LND variants provide an unusual window on the spectrum
of dystonia. Dystonia is obvious when it is fully developed with
twisting movements and odd postures, but its mildest expressions
often are harder to recognize. By extrapolating from what is more
clearly dystonia in more seriously affected classic LND cases, it
seems likely that more mildly affected cases exemplify more
Table 3 Presenting features in previously reported cases
Presenting feature Number (n=97) Percent of total
Neurological 19 19.6
Motor delay 12 12.4
Seizures 3 3.1
Speech impediment 2 2.1
Encephalopathy 1 1.0
Toe walking 1 1.0
Urological 38 39.2
Colic 17 17.5
Renal failure 13 13.4
Crystalluria 9 9.3
Haematuria 8 8.2
Nephrolithiasis 7 7.2
Dysuria 2 2.1
Other urate-related 29 29.9
Gout 26 26.8
Hyperuricemia 3 3.1
Miscellaneous 11 11.3
Affected relative 7 7.2
Failure to thrive 2 2.1
Screening program 1 1.0
Fevers 1 1.0
Presenting features in 97 of the 109 unique cases where information concerning
presentation was available. The subgroups may sum to more than the total since
some cases presented with more than one problem.
Table 4 Neurological features in previously reported cases
Feature Number (n=47) Percent of total
Extrapyramidal 18 38.3
Choreoathetosis 9 19.1
Dystonia 9 19.1
Athetosis 4 8.5
Pyramidal 19 40.4
Hyperreﬂexia 14 29.8
Spasticity 11 23.4
Clonus 2 4.3
Other 28 59.6
Dysarthria 19 40.4
Seizures 7 14.9
Ataxia 2 4.3
Tremor 2 4.3
Neurological features in 47 of the 109 unique cases were information was
presented. The subgroups may sum to more than the total since some cases
presented with more than one problem. The table is based on originally reported
terminology with no effort to re-interpret accuracy when the term conﬂicted with
actual clinical descriptions.
Lesch–Nyhan variants Brain 2010: 133; 671–689 | 681subtle forms of dystonia. For example, the hyperlordotic postures
seen in some variants may reﬂect milder expressions of the more
severe truncal dystonia and opisthotonic postures common in clas-
sic LND (Jinnah et al., 2006). Stuttering and hesitant speech may
constitute an action dystonia, as previously suggested (Kiziltan and
Akalin, 1996; Puig et al., 2008). Clumsy hand movements or gaits
with a ‘stiff’ or ‘heavy’ appearance may reﬂect the mildest expres-
sions of dystonia. If this interpretation is correct, the implication is
that the frequency of dystonia is much higher than current appre-
ciated in the LND variants and perhaps other disorders too.
The spectrum of cognitive abnormalities
Our studies and others in the literature also call attention to
cognitive dysfunction in the LND variants (Schretlen et al.,
2001). Our studies suggest that cognitive dysfunction is more fre-
quent than previously appreciated. The difference again probably
involves methods of assessment. Cognitive assessments frequently
under-estimate disability when they rely only on clinical impres-
sions without formal neuropsychological testing. Several of our
patients thought to be cognitively normal based on global clinical
impressions were found to have signiﬁcant cognitive disability after
formal neuropsychological testing. Others with broadly normal IQs
showed more selective deﬁcits in speciﬁc cognitive domains.
However, cognitive dysfunction usually is not severe. Most
patients had IQ scores in the borderline to low-average range
(70–89).
The spectrum of behavioural
abnormalities
Patients with classic LND display a characteristic behavioural phe-
notype that includes self-injurious behaviours, impulsive acts of
aggression such as striking out or spitting, and use of foul or
sexually charged language (Nyhan, 1976; Anderson and Ernst,
1994; Schretlen et al., 2005). Self-injurious behaviour was an
exclusionary criterion for deﬁning a variant form of LND, so it
was absent from the current series. However, our studies are con-
sistent with the literature in implying that behaviour in the LND
variants may not always be normal. Five LND variants exhibited
behaviours potentially related to self-injury, such as habitual ﬁn-
gernail biting. It is tempting to speculate that this onychophagia is
a forme fruste of more serious ﬁnger biting, which is the com-
monest expression of self-injury in classic LND (Anderson and
Ernst, 1994; Schretlen et al., 2005).
Other socially difﬁcult behaviours, such as impulsivity, severe
enough to warrant medical attention also were common in the
LND variants. Similar problems have been described before, such
as one case who was noted to act on impulses to jump from a
moving vehicle or insert a nail into an electric outlet (Geerdink
et al., 1973). Another LND variant was noted to have precipi-
tously pulled out a large patch of hair from his head for no appar-
ent reason, and to have exhibited antisocial behaviour that led to
incarceration (Nyhan, 1978). These cases may not reach strict def-
initions of self-injurious behaviour that involve tissue injury, but it
is important to acknowledge that the criterion for tissue injury for
deﬁnition of self-injury is somewhat arbitrary. Distinctions between
the variant and LND cases are further blurred by classic cases of
LND with very mild or late-onset of self-injury. One of our classic
LND patients had very mild self-injury limited to a hypertrophic
abrasion on one thumb due to repetitive hand-to-mouth beha-
viour, but without overt bleeding from biting (Jinnah et al.,
2006). A review of the literature discloses that self-injury typically
arises before 4years of age, but may be delayed until late teenage
years, when it often is infrequent or mild (Fig. 2). These observa-
tions suggest a spectrum of maladaptive behaviour across classic
and variant LND rather than an all-or-none phenomenon, a sug-
gestion supported by a study with standardized behavioural rating
Figure 1 Schematic representation of the spectrum of clinical features in LND and its variants. Patients are divided into subgroups with
the most severe being LND, the intermediate form being HPRT-related neurological dysfunction (HND), and the least severely affected
being HPRT-related hyperuricaemia (HRH). The frequency or severity of each problem is depicted by the thickness of the tapering bar,
with description of the spectrum of the problem across the groups.
682 | Brain 2010: 133; 671–689 H. A. Jinnah et al.scales showing the LND variants score between those of normal
and classic LND in nearly every problem behaviour category
(Schretlen et al., 2005).
The spectrum of uric acid abnormalities
There also are signiﬁcant variations in the severity of problems due
to uric acid, though these were not systematically evaluated in our
patients. Efforts to address uric acid problems are challenging
because its overproduction is treated with allopurinol as soon as
it is recognized. As a result, uric acid complications reﬂect primarily
the efﬁcacy of treatment rather than variations in disease severity.
Prior studies have indicated that overproduction of uric acid
does not differ between classic and variant cases (Mateos and
Puig, 1994; Jinnah and Friedmann, 2001; Puig et al., 2001).
However, these studies were limited by relatively small numbers.
When considering all available uric acid measures in untreated
patients reported in the literature, a signiﬁcant difference between
the patient subgroups becomes evident (Table 5). Further studies
are needed that control for age, renal function, and other variables
known to affect uric acid measures independent of HPRT
deﬁciency.
Despite the spectrum of problems related to uric acid, it seems
unlikely that they are causally related to the neurological or beha-
vioural problems in LND. Treatment of LND patients from birth
with allopurinol does not inﬂuence the development of neurobe-
havioural problems, and there are other clinical disorders with
excessive production of uric acid but without the neurobehavioural
problems of LND (Jinnah and Friedmann, 2001).
Patterns of disease and nosology
The relatively large number of LND variants evaluated here com-
bined with our prior study of classic LND (Jinnah et al., 2006)
facilitates the identiﬁcation of patterns of disease rather than a
random assortment of phenotypic abnormalities (Fig. 1). For
example, self-injurious behaviour in classic LND typically is asso-
ciated with the most severe motor dysfunction and the most
prominent cognitive disability. Patients with little or no motor
abnormalities appear to have less cognitive impairment, with a
signiﬁcant correlation of BFM scores with IQ (Fig. 3). Although
exceptions exist, these observations suggest the overall clinical
phenotype occurs as a continuously graded spectrum of severity.
Despite this spectrum, there is both heuristic and practical value
for deﬁning subgroups for clinical studies, treatment of speciﬁc
features, and counselling. The spectrum of disease most com-
monly has been divided into three groups (Sege-Peterson et al.,
1992; Jinnah and Friedmann, 2001). The most severe phenotype is
designated as classic LND, which encompasses overproduction of
uric acid with all the neurological manifestations including
self-injurious behaviours. An intermediate group includes uric
acid overproduction with varying degrees of motor disability, but
self-injury is absent. These patients have been designated
HPRT-related neurological dysfunction. The least severely affected
group has been designated HPRT-related hyperuricaemia, which
includes patients with uric acid overproduction, but clinically insig-
niﬁcant neurological or behavioural deﬁcits. Essentially, the occur-
rence of self-injurious behaviour distinguishes classic patients from
variants, and clinically apparent motor disability distinguishes the
variants into those with and without neurological impairment.
When dystonia is rated with the BFM scale and stratiﬁed
according to these subgroups, there is considerable overlap but
good correspondence between severity and clinical subgroup
(Fig. 4). This result is expected because motor dysfunction falls
on a continuous spectrum and is a criterion for distinguishing
the LND variants. The BFM also discriminates LND from variants,
even though it is not a criterion for separating these groups. Using
IQ as an estimate of cognition, there again is signiﬁcant overlap
but a good correspondence between median scores and clinical
subgroup (Fig. 5), even though IQ is not a criterion for
Figure 2 Histogram showing age at onset of self-injury in pre-
viously reported cases of classic LND. Among 349 classic LND
cases described in 133 previous reports, the age at onset of
self-injury was available for 212 cases. Cases were binned in
yearly increments, with a mean age of 3.12.5 and a median
age of 2years.
Table 5 Serum and urine uric acid in classic and
variant LND
Patient group Serum uric
acid (mg/dl)
Urine uric acid
(mg/kg per 24h)
Urine uric acid/
creatinine ratio
Classic LND 11.74.8 42.617.3 3.21.1
HPRT-related
neurological
dysfunction
13.03.8 33.613.1 1.60.8
HPRT-related
hyperuricaemia
12.45.7 23.99.8 1.00.5
Uric acid measures for 349 classic and 125 variant cases of LND reported in the
prior literature. To avoid skewing the results by over-representation of individual
samples, multiple values or ranges of values reported for any one case were
averaged to give a single value. When multiple values were reported over several
years for one case, only the ﬁrst value was used, since serum uric acid varies
according to age and the values could not be averaged. We excluded values from
patients who were receiving drugs known to alter uric acid. Statistical comparisons
were conducted via the Kruskal–Wallis test for non-parametric data, which
revealed signiﬁcant group differences for 24h urinary uric acid (P=0.003) and uric
acid/creatinine ratios (P50.001) but not for serum uric acid (P=0.13).
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be internally consistent in distinguishing grades of severity.
Some caveats regarding nosology
Despite the internal consistency of the proposed nosological clas-
siﬁcation, some caveats must be noted. First, BFM scores are not
normally distributed, but instead suggest a bimodal population
(Figs 3 and 4). This ﬁnding might support a two-group classiﬁca-
tion system as previously suggested (Kelley et al., 1969).
However, the lack of a normal distribution could reﬂect an artefact
of insufﬁcient numbers of patients with intermediate severity,
non-linearity of the BFM scale, more frequent progression of
patients with intermediate scores, or recurrent mutations that
result in non-random clinical outcomes. For example, the C151T
hotspot that encodes a null enzyme generates an overrepresenta-
tion of classic patients (Jinnah et al., 2000, 2006), and the recur-
rent G143A mutation that encodes a partially dysfunctional
enzyme creates an overrepresentation of very mildly affected
patients (Tables 1 and 2).
The second caveat is that despite the overall correlation
between BFM scores and IQ in our patients, signiﬁcant discrepan-
cies exist, suggesting the lack of exact correspondence between
motor and cognitive function (Fig. 3). It is important to acknowl-
edge that cognitive function was not methodically assessed with
the same instruments across all patients due to differences in age
and language, and IQ scores may not capture signiﬁcant deﬁcits in
speciﬁc cognitive domains. Further studies of cognitive domains
most affected, such as attention, may provide more useful mea-
sures than overall IQ for deﬁning clinically relevant subgroups.
However, since motor and cognitive dysfunction may be dissoci-
able, it seems reasonable to consider signiﬁcant cognitive dysfunc-
tion as a criterion for reclassifying a patient with HPRT-related
hyperuricaemia to HPRT-related neurological dysfunction, regard-
less of any motor disability.
The third caveat is that corticospinal motor signs do no seem to
show graded severity across the patient groups, since they are
equally frequent and severe in both classic and variant LND
(Fig. 6). This ﬁnding may suggest the pathogenesis of corticospinal
problems is unrelated to the pathogenesis of the extrapyramidal
features. However, corticospinal signs are minor compared to
Figure 3 Correlations between dystonia and cognition.
Dystonia was rated with the BFM dystonia rating scale, with mild
motor deﬁcits scored as mild expressions of dystonia. Scores for
patients with LND come from our previous study (Jinnah et al.,
2006) while those for variants come from Tables 1 and 2.
Cognition was assessed with IQ, which was taken from the
results of clinical diagnostic testing or previous publications.
Patient subgroups are LND (circles), HPRT-related neurological
dysfunction (squares), and HPRT-related hyperuricaemia (trian-
gles). Patients with LND and HPRT-related neurological dys-
function were distinguished by the presence of self-injurious
behaviour. The HPRT-related hyperuricaemia group was deﬁned
as clinically insigniﬁcant motor dysfunction with a BFM score of
5 or less. There was a signiﬁcant negative correlation between
BFM and IQ scores (Spearman rho=0.64, P50.001). This
correlation remained after controlling for age (Spearman
rho=0.63, P50.001). There was no signiﬁcant correlation
between BFM and age (Spearman rho=0.20, P=0.21).
Figure 4 Severity of dystonia according to patient subgroup.
Dystonia was rated with the BFM dystonia rating scale, with mild
motor deﬁcits scored as mild expressions of dystonia. Patient
subgroups are LND, HPRT-related neurological dysfunction
(HND), and HPRT-related hyperuricaemia (HRH). Patients with
LND and HPRT-related neurological dysfunction were distin-
guished by the presence of self-injurious behaviour. The
HPRT-related hyperuricaemia group was deﬁned as clinically
insigniﬁcant motor dysfunction with a BFM score of 5 or less.
Scores for patients with LND come from our previous study
(Jinnah et al., 2006) while those for variants come from Tables 1
and 2. Individual scores are overlaid with a box-whisker plot,
where the middle horizontal line in each box shows the median.
The upper and lower limits of the box deﬁne the upper and
lower quartiles. Whiskers span the entire data range excepting
outliers, deﬁned as values that fell outside the upper or lower
quartile plus 1.5 times the inter-quartile distance. The groups
were compared statistically using the Kruskal–Wallis H-statistic,
which revealed overall signiﬁcance at P50.0001. Post hoc
Wilcoxin signed ranked tests revealed signiﬁcant differences
(P50.001) between each of the groups.
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patient classiﬁcation. There also are rare reports of patients with
clinical features not found in our patients. Two cases from the
literature were reported to have a spinocerebellar syndrome
(Kelley et al., 1969) and another was reported to have ataxia
with dystonia (Adler and Wrabetz, 1996). However, the ﬁrst
two cases were re-evaluated by others who described an extra-
pyramidal syndrome rather than ataxia (Nyhan, 1978). The other
case was re-evaluated here (case DM). Though he had dysmetric
limb movements, they were considered secondary to his severe
generalized dystonia rather than true cerebellar ataxia. This view
is supported by the lack of other features supportive of cerebellar
dysfunction in any of our variant or classic LND cases (Jinnah
et al., 2001, 2006). Thus there seems little evidence for true cer-
ebellar ataxia in LND or its variants, and this feature seems sufﬁ-
ciently infrequent to be considered atypical. Although our studies
focus on the use of clinical features alone for nosological
classiﬁcation, additional molecular and biochemical measures of
the disease may be helpful for validating or reﬁning the classiﬁca-
tion further.
Pathogenesis of phenotypic variation
LND and its variants are caused by different mutations in the
HPRT gene (Table 6). Prior genotype–phenotype comparisons
have suggested that the location and type of gene mutation are
less relevant for predicting the clinical phenotype than the effect
of the mutation on residual enzyme function (Jinnah et al., 2000,
2004). Mutations resulting in little or no residual enzyme function
typically cause classic LND, while mutations permitting residual
activity more often lead to less severely affected LND variants.
The mutations in the current series support this concept, with
the majority resulting in single amino acid substitutions compatible
with residual enzyme function (Table 1). There also were ﬁve
patients with splicing mutations, which are known to be ‘leaky’
and permit variable residual activity (Hunter et al., 1996; O’Neill
et al., 1998; Mak et al., 2000; Gaigl et al., 2001). Four others had
low but detectable mRNA levels leading to low enzyme activity.
One patient had a duplication involving exons 2–3, previously
shown to undergo partial reversion leaving a small amount of
residual enzyme activity (Yang et al., 1988).
The concept that the severest phenotype occurs when HPRT
activity is absent whereas the milder variants have residual
enzyme function is supported by most studies in which enzyme
activity was measured using assay conditions that mimic the
natural state in cultured ﬁbroblasts, lymphocytes, or intact erythro-
cytes (Page et al., 1981; Fairbanks et al., 1987; Page and Nyhan,
1989; Puig et al., 2001). For most cases, there is a good correla-
tion between clinical severity and residual enzyme activity. Rare
case reports where enzyme activity lacks correlation with pheno-
typic severity sometimes are presented as evidence against this
idea (Rijksen et al., 1981; Cossu et al., 2002). These apparent
exceptions most often occur when the enzyme is measured via
assays that do not replicate natural conditions (McDonald and
Kelley, 1971; Dancis et al., 1973; Holland et al., 1976; Bakay
et al., 1979; Cameron et al., 1984; Hersh et al., 1986;
Fairbanks et al., 1987; Zoref-Shani et al., 2000; Jinnah et al.,
2004). All of our LND variants who had enzyme activity measured
in live cells displayed measurable residual activity, and discrepan-
cies between assays from live cells versus lysates were evident for
many cases that had both assays (Table 1). These observations
highlight some problems associated with the lack of standardized
biochemical testing. Though assays based on live cells are more
accurate than those based on cell lysates, most diagnostic centres
use lysate-based assays because they are technically simpler and
less expensive.
The current studies also are consistent with prior studies of clas-
sic LND indicating that pathogenesis involves dysfunction of basal
ganglia circuits (Visser et al., 2000). These circuits have been
divided into several parallel but segregated pathways serving
motor function, cognition, oculomotor control, and behavioural
or ‘limbic’ functions. The most prominent motor abnormality
in LND and its variants is dystonia, which may be attributed to
dysfunction of motor circuits involving the putamen and motor
Figure 5 IQ scores according to patient subgroup. The IQ was
not methodically assessed with a standardized instrument due to
differences in age and language, but instead was taken from the
results of clinical diagnostic testing or previous publications.
Patient subgroups include LND, HPRT-related neurological dys-
function (HND), and HPRT-related hyperuricaemia (HRH).
Patients with LND and HPRT-related neurological dysfunction
were distinguished by the presence of self-injurious behaviour.
The HPRT-related hyperuricaemia group was deﬁned as clinically
insigniﬁcant motor dysfunction with a BFM score of 5 or less.
Scores for patients with LND come from our previous study
(Jinnah et al., 2006) while those for variants come from Tables 1
and 2. Individual scores are overlaid with a box-whisker plot,
where the middle horizontal line in each box shows the median.
The upper and lower limits of the box deﬁne the upper and
lower quartiles. Whiskers span the entire data range excepting
outliers, deﬁned as values that fell outside the upper or lower
quartile plus 1.5 times the inter-quartile distance. The groups
were compared statistically using the Kruskal–Wallis H-statistic,
which revealed overall signiﬁcance at P50.0001. Post hoc
Wilcoxin signed ranked tests revealed signiﬁcant differences
(P50.001) between the LND and each of the other two groups.
The difference between HPRT-related neurological dysfunction
and HPRT-related hyperuricaemia groups was not signiﬁcant
(P=0.56).
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defects in attention may be attributed to dysfunction of circuits
involving the caudate and frontal cortices (Schretlen et al., 2001).
The characteristic ocular motor apraxia with saccadic distractability
in LND and its variants resembles the oculomotor defects of
Huntington’s disease, which have been linked with the caudate
and frontal cortex eye ﬁelds (Jinnah et al., 2001). Finally,
self-injurious and other difﬁcult behaviours can be attributed to
pathways through the ventral striatum and mediobasal frontal
cortex (Visser et al., 2000).
Dysfunction of basal ganglia circuits in LND and its variants
appears to be related to selective vulnerability of dopaminergic
neurons. Although these constitute only small population of
neurons, they have a profound modulatory inﬂuence on corticos-
triatal physiology. Post-mortem neurochemical studies have
revealed 60–90% loss of dopamine in the basal ganglia (Lloyd
et al., 1981; Saito et al., 1999), and PET studies have shown
similar reductions in ﬂuorodopa uptake or dopamine transporters
in the basal ganglia (Ernst et al., 1996; Wong et al., 1996). A
selective loss of dopamine also is seen in the basal ganglia in HPRT
knockout mice (Jinnah et al., 1992, 1994, 1999), and in cultured
HPRT-deﬁcient dopaminergic neurons (Bitler and Howard, 1986;
Yeh et al., 1998; Lewers et al., 2008). Histopathological studies of
autopsied brain tissue or the HPRT knockout mice do not show a
loss of midbrain dopamine neurons, suggesting the loss of dopa-
mine reﬂects a metabolic rather than a degenerative process (Del
Bigio and Halliday, 2007; Egami et al., 2007; Ceballos-Picot et al.,
2009). In this regard, LND resembles DOPA-responsive dystonia
more than it resembles Parkinson’s disease.
Although the most prominent clinical features in LND and its
variants may be attributed to dysfunction of the basal ganglia,
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Figure 6 Motor features in classic versus variant LND. The percent of patients in the current series of LND variants (LNV; n=46, black
bars) is compared with the percent of patients with classic LND (n=44, grey bars) from our prior studies (Jinnah et al., 2006). Panel A
depicts extrapyramidal features while Panel B depicts pyramidal features.
Table 6 Mutations of the HPRT gene in classic and variant
LND
Mutation class LND
(n=280)
LNV
(n=101)
NA
(n=9)
Total
(n=390)
Single base substitution
Missense
a 86 76 4 167
Nonsense
b 29 1 1 31
Splice site
c 44 11 0 55
Deletions
Coding sequences 80 2 4 86
Splice site 5 0 0 5
Insertions
Coding sequences 22 1 0 23
Splice site 1 0 0 1
Miscellaneous
Duplications 3 3 0 6
Substitutions 4 1 0 5
Regulatory elements
d 03 03
Female cases
e 61 07
Double mutants 0 2 0 2
The genetic mutations in the HPRT gene for both classic cases (LND) and the less
seriously affected variants (LNV). The clinical subtype for some patients could not
be determined because of insufﬁcient information in some of the reports (NA). A
complete list of individual mutations and associated publications can be found at
http://www.lesch-nyhan.org.
aSingle base change leading to single amino acid subsitution.
bSingle base change leading to premature termination of protein translation.
cSingle base change leading to intron/exon splicing defect.
dUnidentiﬁed promoter or enhancer non-coding sequence change resulting in
reduced mRNA.
eAll females have had an identiﬁable mutation on one allele combined with
non-random X-inactivation.
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ﬂexia and clonus provide evidence for dysfunction of corticospinal
motor pathways. Cognitive limitations also may reﬂect involve-
ment of the cerebral cortex. Contrary to a recent claim (Del
Bigio and Halliday, 2007), there seems little evidence for clinically
signiﬁcant cerebellar ataxia.
Diagnosis
The diagnosis of classic LND is relatively straightforward when all
the telltale clinical features, including self-injury, are apparent.
Diagnosis is more challenging in variants with attenuated syn-
dromes. The differential diagnosis of early-onset dystonia or clum-
siness, with or without cognitive impairment, is broad. Ancillary
neurological testing with neuroimaging or EEG has limited value.
Instead, overproduction of uric acid, frequently evident as an ele-
vated serum uric acid, is one of the most useful clues (Jinnah and
Friedmann, 2001). Hyperuricaemia is uncommon below 40 years
of age and should prompt further evaluation, especially if it is
combined with evidence for motor or cognitive impairment.
Patients for whom diagnoses are delayed ultimately develop one
of the consequences of hyperuricaemia, such as nephrolithiasis or
gout, both of which are uncommon before 40 years of age
(Cameron et al., 1993). The development of either problem in a
young person with motor or cognitive abnormalities also should
lead to further testing.
Hyperuricaemia provides a useful early clue, but it is not ade-
quate for deﬁnitive diagnosis. Serum uric acid is highly dependent
on many factors including hydration, diet, medications and renal
efﬁciency. A few LND variants have persistently normal serum uric
acid, and many have elevations that are sufﬁciently small to
escape notice. Molecular testing for a mutation in the HPRT
gene provides a reliable means of diagnosis (Jinnah et al.,
2000). The gene test also facilitates carrier diagnosis and prenatal
testing. The main shortcoming of molecular testing is that muta-
tions must be identiﬁed by sequencing the gene because they are
heterogeneous. Since this process is time-consuming and expen-
sive, it is offered by only a handful of centres worldwide (http://
www.lesch-nyhan.org). Another shortcoming is that mutation
screening will miss the unusual cases of HPRT deﬁciency that
are due to non-coding reductions in HPRT mRNA expression
(Dawson et al., 2005; Garcia et al., 2008). Finally, unique muta-
tions have little prognostic value.
Another option for diagnostic testing is biochemical measure-
ment of HPRT enzyme activity (Jinnah et al., 2004). Since
assays of live cells provide enzyme measures that correlate with
disease severity, they may have predictive value for prognosis.
However, they are technically demanding and offered by only a
few centres worldwide. Nevertheless, further studies addressing
the most appropriate biochemical assays could be valuable for
counselling of cases diagnosed early.
Summary
These studies provide the largest summary to date for the spec-
trum of neurological manifestations that can occur in association
with HPRT deﬁciency. The results are valuable for raising
awareness of atypical presentations of this rare disease, where
diagnosis is challenging. The LND variants may lack clinically
apparent cognitive dysfunction or overtly abnormal behaviour
characteristic of the classic phenotype. Motor function may
range from normal to severe disability, with the most common
problem being varying manifestations of dystonia. These studies
also are valuable for pointing to clues for the diagnosis, as well as
diagnostic methods and their limitations. Early diagnosis is impor-
tant because some of the manifestations such as those related to
uric acid are treatable, and because early recognition facilitates
carrier identiﬁcation for family counselling.
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